

Technical Disclosure Commons

Defensive Publications Series

July 2022

Improved process for the preparation of methyl 2-oxoindoline-6-carboxylate

MSN Laboratories Private Limited, R&D Center; Srinivasan Thirumalai Rajan; Sajja Eswaraiah; M. Kishore; M Ramakrishna; Mukunda Reddy Panduga

Follow this and additional works at: https://www.tdcommons.org/dpubs_series

Recommended Citation

MSN Laboratories Private Limited, R&D Center; Srinivasan Thirumalai Rajan; Sajja Eswaraiah; M. Kishore; M Ramakrishna; Mukunda Reddy Panduga, "Improved process for the preparation of methyl 2-oxoindoline-6-carboxylate", Technical Disclosure Commons, (July 01, 2022)
https://www.tdcommons.org/dpubs_series/5234




This work is licensed under a [Creative Commons Attribution 4.0 License](https://creativecommons.org/licenses/by/4.0/).

This Article is brought to you for free and open access by Technical Disclosure Commons. It has been accepted for inclusion in Defensive Publications Series by an authorized administrator of Technical Disclosure Commons.

Improved process for the preparation of methyl 2-oxoindoline-6-carboxylate

Abstract:

The present invention provides a process for the preparation of methyl 2-oxoindoline-6-carboxylate of formula-1, which is represented by the following structural formula:




Formula-1

Introduction:

Methyl 2-oxoindoline-6-carboxylate of formula-1 is key intermediate for the preparation of Nintedanib esylate.

Nintedanib esylate is chemically known as 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-,methyl ester, (3Z)-, ethanesulfonate (1:1).



Nintedanib esylate

Nintedanib is a small molecule tyrosine kinase inhibitor including the receptors platelet-derived growth factor receptor (PDGFR) α and β , fibroblast growth factor receptor (FGFR) 1-3, and VEGFR 1-3. Nintedanib binds competitively to the ATP binding pocket of these receptors and blocks the intracellular signalling. In addition, nintedanib inhibits Flt-3 (Fms-like tyrosine-protein kinase), Lck (lymphocyte-specific tyrosine-protein kinase), Lyn (tyrosine-protein kinase lyn) and Src (proto-oncogene tyrosine-protein kinase src) kinases.


Nintedanib inhibits the activation of FGFR and PDGFR signalling cascades which are critically involved in proliferation, migration and differentiation of lung fibroblasts/myofibroblasts, the hallmark cells in the pathology of idiopathic pulmonary

fibrosis. The potential impact of VEGFR inhibition by nintedanib and the anti-angiogenic activity of nintedanib on IPF pathology are currently not fully elucidated. In preclinical disease models of lung fibrosis nintedanib exerts potent anti-fibrotic and anti-inflammatory activity. Nintedanib inhibits proliferation, migration and fibroblast to myofibroblast transformation of human lung fibroblasts from patients with IPF.

Nintedanib, marketed under the brand names Ofev and Vargatef, is a medication used for the treatment of idiopathic pulmonary fibrosis (IPF) and along with other medications for some types of non-small-cell lung cancer.

Nintedanib and its pharmaceutical acceptable salts was disclosed in US6762180 B1.

Disclosed herein the process for the preparation of methyl 2-oxoindoline-6-carboxylate of formula-1, schematically as mentioned below:



The compound of formula-4 used in the present invention can be prepared from any of the processes known in the art.

Experimental Section:

Example-1: Preparation of methyl 4-chloro-3-nitrobenzoate of Formula-3.

Methanol (500.0 ml) was added to 4-chloro-3-nitrobenzoic acid of formula-4 (100.0 gm) at 25-30°C and stirred for 10 minutes. Thionyl chloride (30.0 gm) was slowly added to the mixture at 25-30°C and stirred for 40 minutes. Heated the mixture to 60-65°C and stirred for 3 hours. Distilled off the mixture and co-distilled with isopropanol. Isopropanol (300.0 ml) was

added to the obtained compound at 60-65°C and stirred for 30 minutes. Cooled the mixture to 0-5°C and stirred for 2 hours. Filtered the solid, washed with isopropanol and dried to get the title compound. Yield: 102 gm.

Example-2: Preparation of dimethyl [4-(methoxycarbonyl)-2-nitrophenyl]propanedioate of Formula-2.

Potassium tert-butoxide (52.0 gm) and dimethyl sulfoxide (150.0 ml) were added to dimethyl malonate (52.0 gm) at 25-30°C. Cooled the mixture to 20-25°C and stirred for 2 hours. Compound of formula-3 (50.0 gm) was slowly added to the mixture at 20-25°C and stirred for 2 hours. Hydrochloric acid was added to the mixture at 20-25°C. Sodium chloride (20.0 gm) and methyl tert-butyl ether (250.0 ml) were added to the mixture at 25-30°C and stirred for 10 minutes. Layers were separated and aqueous layer was extracted with methyl tert-butyl ether. Distilled off the organic layer at below 50°C to get the title compound. Yield: 53.0 gm.

Example-3: Preparation of methyl 2-oxoindoline-6-carboxylate of Formula-1.

Acetic acid (250.0 ml) was added to compound of formula-2 (50.0 gm) at 25-30°C. Hydrose (83.9 gm) and water (250.0 ml) were added to the mixture at 25-30°C and stirred for 10 minutes. Heated the mixture to 120-125°C and stirred for 2 hours. Cooled the mixture to 15-20°C. Ammonia (500.0 ml) was added to the mixture at 15-20°C and stirred for 2 hours. Filtered the solid, washed with water and dried to get the title compound. Yield: 22.0 gm.
